GSE230372 L-27 CAL-27 LEF1 1 v 0 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE230372_L-27_CAL-27 LEF1_1_v_0_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE230372_L-27_CAL-27 LEF1_1_v_0_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE230372_L-27_CAL-27 LEF1_1_v_0_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE230372_L-27_CAL-27 LEF1_1_v_0_human_up.

Results found

Linked to

 

Label

Description

 

Gene

tripartite motif containing 16 like (pseudogene)

Gene

lung cancer associated transcript 1

Gene

ZNF496 divergent transcript

Gene

FBXL19 antisense RNA 1

Gene

long intergenic non-protein coding RNA 2577

Gene

surfactant associated 1, lncRNA

Gene

BCAN antisense RNA 2

Gene

SH3BP5 antisense RNA 1

Gene

PAXIP1 divergent transcript

Gene

long intergenic non-protein coding RNA 339

  • Gene

    tripartite motif containing 16 like (pseudogene)


  • Gene

    lung cancer associated transcript 1


  • Gene

    ZNF496 divergent transcript


  • Gene

    FBXL19 antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 2577


  • Gene

    surfactant associated 1, lncRNA


  • Gene

    BCAN antisense RNA 2


  • Gene

    SH3BP5 antisense RNA 1


  • Gene

    PAXIP1 divergent transcript


  • Gene

    long intergenic non-protein coding RNA 339

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.